ATTO · Forms 3, 4, 5
Insider trades at Attovia Therapeutics, Inc.
2 insiders sold $4.5M and 6 insiders bought $52.4M of Attovia Therapeutics, Inc. stock on the open market in the last 90 days.
Every Form 3, 4 and 5 filed for Attovia Therapeutics, Inc. (ATTO) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Insider trades in the last 90 days
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Colin Walsh | Director | Conversion | 1,957,134 | Form 4 | |||
| Colin Walsh | Director | Conversion | 478,498 | Form 4 | |||
| Colin Walsh | Director | Buy | 500,000 | $17.00 | $8.5M | Form 4 | |
| GOLDMAN SACHS GROUP INC | Conversion | 1,957,134 | Form 4 | ||||
| GOLDMAN SACHS GROUP INC | Conversion | 478,498 | Form 4 | ||||
| GOLDMAN SACHS GROUP INC | Buy | 500,000 | $17.00 | $8.5M | Form 4 | ||
| Deep Track Biotechnology Master Fund, Ltd. | 10% owner | Conversion | 1,957,138 | Form 4 | |||
| venBio Global Strategic Fund IV, L.P. | 10% owner | Conversion | 2,311,870 | Form 4 | |||
| venBio Global Strategic Fund IV, L.P. | 10% owner | Conversion | 821,998 | Form 4 | |||
| venBio Global Strategic Fund IV, L.P. | 10% owner | Conversion | 665,147 | Form 4 | |||
| venBio Global Strategic Fund IV, L.P. | 10% owner | Buy | 382,352 | $17.00 | $6.5M | Form 4 | |
| Redmile Group, LLC | 10% owner | Conversion | 782,854 | Form 4 | |||
| Redmile Group, LLC | 10% owner | Buy | 200,000 | $17.00 | $3.4M | Form 4 | |
| Redmile Group, LLC | 10% owner | Buy | 400,000 | $17.00 | $6.8M | Form 4 | |
| Sanofi | 10% owner | Conversion | 782,855 | Form 4 | |||
| Sanofi | 10% owner | Buy | 300,000 | $17.00 | $5.1M | Form 4 | |
| Frazier Life Sciences XI, L.P. | 10% owner | Conversion | 1,749,192 | Form 4 | |||
| Frazier Life Sciences XI, L.P. | 10% owner | Conversion | 1,590,175 | Form 4 | |||
| Frazier Life Sciences XI, L.P. | 10% owner | Conversion | 1,189,940 | Form 4 | |||
| Frazier Life Sciences XI, L.P. | 10% owner | Conversion | 961,322 | Form 4 | |||
| Frazier Life Sciences XI, L.P. | 10% owner | Buy | 588,235 | $17.00 | $10M | Form 4 | |
| Angie You | Director | Options or other derivatives | Form 4 | ||||
| Mitchell Gold | Director | Options or other derivatives | Form 4 | ||||
| Zaneta Odrowaz | Chief Business Officer | Options or other derivatives | Form 4 | ||||
| Petter Veiby | Chief Scientific Officer | Options or other derivatives | Form 4 | ||||
| Hubert Chen | Chief Medical Officer | Options or other derivatives | Form 4 | ||||
| Attovia Therapeutics, Inc. | Chief Financial Officer | Options or other derivatives | Form 4 | ||||
| Attovia Therapeutics, Inc. | President and CEO | Options or other derivatives | Form 4 | ||||
| Colin Walsh | Director | Buy | 85,000 | $21.00 | $1.8M | Form 4 | |
| Colin Walsh | Director | Sell | 988 | $22.03 | $22K | Form 4 | |
| Colin Walsh | Director | Sell | 447 | $21.87 | $10K | Form 4 | |
| Colin Walsh | Director | Sell | 1,332 | $22.03 | $29K | Form 4 | |
| Colin Walsh | Director | Sell | 200 | $22.05 | $4K | Form 4 | |
| Colin Walsh | Director | Sell | 1,556 | $22.06 | $34K | Form 4 | |
| Colin Walsh | Director | Sell | 3,402 | $22.02 | $75K | Form 4 | |
| Colin Walsh | Director | Sell | 200 | $22.10 | $4K | Form 4 | |
| Colin Walsh | Director | Sell | 480 | $21.55 | $10K | Form 4 | |
| Colin Walsh | Director | Sell | 100 | $22.11 | $2K | Form 4 | |
| Colin Walsh | Director | Sell | 753 | $21.97 | $17K | Form 4 | |
| Colin Walsh | Director | Sell | 672 | $22.02 | $15K | Form 4 | |
| Colin Walsh | Director | Sell | 6,970 | $22.03 | $154K | Form 4 | |
| Colin Walsh | Director | Sell | 400 | $22.02 | $9K | Form 4 | |
| Colin Walsh | Director | Sell | 1,180 | $21.84 | $26K | Form 4 | |
| Colin Walsh | Director | Sell | 1,040 | $22.05 | $23K | Form 4 | |
| Colin Walsh | Director | Sell | 300 | $20.84 | $6K | Form 4 | |
| Colin Walsh | Director | Sell | 443 | $21.78 | $10K | Form 4 | |
| Colin Walsh | Director | Sell | 200 | $22.05 | $4K | Form 4 | |
| Colin Walsh | Director | Sell | 700 | $22.07 | $15K | Form 4 | |
| Colin Walsh | Director | Sell | 1,163 | $22.19 | $26K | Form 4 | |
| Colin Walsh | Director | Sell | 100 | $21.99 | $2K | Form 4 | |
| Colin Walsh | Director | Sell | 6,763 | $21.61 | $146K | Form 4 | |
| Colin Walsh | Director | Sell | 76,418 | $21.04 | $1.6M | Form 4 | |
| GOLDMAN SACHS GROUP INC | Buy | 85,000 | $21.00 | $1.8M | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 988 | $22.03 | $22K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 447 | $21.87 | $10K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 1,332 | $22.03 | $29K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 200 | $22.05 | $4K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 1,556 | $22.06 | $34K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 3,402 | $22.02 | $75K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 200 | $22.10 | $4K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 480 | $21.55 | $10K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 100 | $22.11 | $2K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 753 | $21.97 | $17K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 672 | $22.02 | $15K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 6,970 | $22.03 | $154K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 400 | $22.02 | $9K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 1,180 | $21.84 | $26K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 1,040 | $22.05 | $23K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 300 | $20.84 | $6K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 443 | $21.78 | $10K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 200 | $22.05 | $4K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 700 | $22.07 | $15K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 1,163 | $22.19 | $26K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 100 | $21.99 | $2K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 6,763 | $21.61 | $146K | Form 4 | ||
| GOLDMAN SACHS GROUP INC | Sell | 76,418 | $21.04 | $1.6M | Form 4 | ||
| Alamar HoldCo, LLC | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Colin Walsh | Director | Became an insider (Form 3) | Form 3 | ||||
| Deep Track Biotechnology Master Fund, Ltd. | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Redmile Group, LLC | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Vida Ventures GP III, L.L.C. | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| venBio Global Strategic Fund IV, L.P. | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Angie You | Director | Became an insider (Form 3) | Form 3 | ||||
| Petter Veiby | Chief Scientific Officer | Became an insider (Form 3) | Form 3 | ||||
| Aaron Royston | Director | Became an insider (Form 3) | Form 3 | ||||
| Attovia Therapeutics, Inc. | Chief Financial Officer | Became an insider (Form 3) | Form 3 | ||||
| Zaneta Odrowaz | Chief Business Officer | Became an insider (Form 3) | Form 3 | ||||
| Attovia Therapeutics, Inc. | President and CEO | Became an insider (Form 3) | Form 3 | ||||
| Mitchell Gold | Director | Became an insider (Form 3) | Form 3 | ||||
| James N Topper | Director | Became an insider (Form 3) | Form 3 | ||||
| Hubert Chen | Chief Medical Officer | Became an insider (Form 3) | Form 3 | ||||
| John W Smither | Director | Became an insider (Form 3) | Form 3 | ||||
| GOLDMAN SACHS GROUP INC | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Frazier Life Sciences XI, L.P. | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Sanofi | 10% owner | Became an insider (Form 3) | Form 3 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.